Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFNT-211 in Advanced Solid Tumors with KRAS G12V Mutation
NCT06105021Phase 2Active, not recruiting
- Sponsor
- Affini-T Therapeutics
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of Mutant KRAS G12V-specific TCR transduced autologous T cells in solid tumor, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 1 more (5 arms), sponsored by Affini-T Therapeutics. Primary endpoints: Optimal Biological Dose at 60 months, Recommended Phase 2 Dose at 60 months and 3 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
Mutant KRAS G12V-specific TCR transduced autologous T cells
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06105021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105021.